Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Novavax, Inc. is a biotechnology company focused on developing innovative vaccines for infectious diseases, with a notable emphasis on its protein-based COVID-19 vaccine candidate. The company operates primarily in the U.S. and has a strong pipeline that includes candidates for influenza and other respiratory viruses, positioning it as a key player in the vaccine market.
Novavax generates revenue primarily through the sale of its vaccines, particularly its COVID-19 vaccine, which has received emergency use authorization in multiple markets. The company benefits from high gross margins due to its proprietary technology and partnerships with governments and health organizations, allowing for significant pricing power.
Regulatory approvals for new vaccine candidates
Sales performance of the COVID-19 vaccine in global markets
Partnership announcements with governments or pharmaceutical companies
Clinical trial results for pipeline products
Regulatory changes impacting vaccine approvals
Technological disruption in vaccine development
Emergence of new competitors with more effective vaccines
Price competition from established vaccine manufacturers
Negative operating cash flow impacting liquidity
Dependence on government contracts for revenue
moderate - The demand for vaccines can be somewhat insulated from economic cycles, but overall healthcare spending is influenced by GDP growth and consumer spending.
Interest rates have a minimal direct impact on Novavax as it primarily relies on government funding and grants for vaccine development. However, higher rates could affect overall healthcare budgets and spending.
minimal - Novavax has a negative debt-to-equity ratio, indicating it does not rely heavily on debt financing.
growth - Investors are likely attracted to Novavax for its potential high growth in vaccine sales and innovative pipeline.
high - The stock has exhibited high volatility due to the nature of biotech stocks and reliance on clinical trial outcomes.